Inhibitors of leucine-rich repeat kinase 2 (LRRK2): Progress and promise for the treatment of Parkinson’s disease

Current Topics in Medicinal Chemistry

Volumn 15, Issue 10, 2015, Pages 927-938

  Gilligan, Paul J ^a  

^a Pennsylvania Drug Discovery Institute   (United States)

Author keywords

Kinase inhibitors; Leucine rich repeat kinase 2 (LRRK2); Parkinson s disease

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5, 6, 7, 8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL) BENZAMIDE; 4 [4 (4 METHYL 1 PIPERAZINYL) 1 PIPERIDINYL] PHENYL] AMINO] PYRIMIDINE; ADENOSINE TRIPHOSPHATE; ALPHA SYNUCLEIN; ANAPLASTIC LYMPHOMA KINASE; CD135 ANTIGEN; DOPAMINE RECEPTOR STIMULATING AGENT; GSK2578125A; INITIATION FACTOR 4E BINDING PROTEIN 1; JANUS KINASE 2; KHEAD TRANSCRIPTION FACTOR; LEUCINE RICH REPEAT KINASE 2; LEUCINE RICH REPEAT KINASE 2 INHIBITOR; MYELIN BASIC PROTEIN; PROTEIN SERINE THREONINE KINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; STAUROSPORINE; SUNITINIB; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG; LRRK2 PROTEIN, HUMAN; LRRK2 PROTEIN, MOUSE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE;

ARTICLE; AUTOPHOSPHORYLATION; CELL CYCLE; DISEASE COURSE; DRUG SELECTIVITY; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENETIC VARIABILITY; HELA CELL LINE; HIGH THROUGHPUT SCREENING; IC50; MISSENSE MUTATION; MOLECULAR DOCKING; MOTOR PERFORMANCE; NEUROPROTECTION; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY; ANIMAL; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; HUMAN; METABOLISM;

ANIMALS; HUMANS; PARKINSON DISEASE; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES;

EID: 84928881238     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802661510150328223655     Document Type: Article

References (64)

1. Healy, D.G.; Falchi, M.; O’Sullivan, S.; Bonifati, V.; Durr, A.; Bressman, S.; Brice, A.; Aaslyj, J.; Zabetian, C.P.; Goldwurm, S.; Ferreira, J.J.; Tolosa, E.; Kay, D.M.; Klein, C.; Williams, D.R.; Marras, C.; Lang, A. E.; Wszolek, Z.K.; Berciano, J.; Shapira, A.H.V.; Lynch, T.; Bhatia, K.P.; Gasser, T.; Lees, A.J.; Wood, N.W. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study, Lancet Neurol., 2008, 7, 583-590.
2. Davie, C.A. A review of Parkinson’s disease. Br. Med. Bull., 2008, 86, 109-127.
3. Jankovic, J. Parkinson’s disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry, 2008, 79, 368-376.
4. Gelb, D.J.; Oliver, E.; Gilman, S. Diagnostic criteria for Parkinson disease, Arch. Neurol. 1999, 56, 33-39.
5. Zimprich, A.; Biskup, S.; Leitner, P.; Lichtner, P.; Farrer, M.; Lincoln, S.; Kachergus, J.; Hulihan, M.; Uitti, R.J.; Calne, D.B.; Stoessl, A.J., Pfeiffer, R.F.; Patenge, N., Carbajal, I.C.; Vierregge, P.; Asmus, F.; Meiller-Myhosek, B.; Dickson, D.W.; Meitinger, T.; Strom, T.M.; Wszolek, Z.K.; Gasser, T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology, Neuron, 2004, 44, 601-607.
6. Berwick, D.C.; Harvey, K. LRRK2 signaling pathways: the key to unlocking neurodegeneration? Trends Cell. Biol., 2011, 21, 257-265.
7. Covy, J.P.; Giasson, B.J. Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of parkinson disease, Neurotoxiciology, 2011, 32, 622-629.
8. Smith, K. Treatment frontiers. Nature-Parkinson’s Disease Outlook, 2010, 466, 15-18.
9. Poewe, W. The natural history of Parkinson’s disease, J.Neurol., 2006, 253(Suppl. 7), VII/2-VII/6.
10. Kruger, R.; Kuhn, W.; Muller, T.; Woitalla, D.; Graeber, M.; Kosel, S.; Przuntek, H.; Eppelen, J.T.; Schols, L.; Reiss, O. Ala30Pro mutation in the gene encoding synuclein in Parkinson’s disease, Nat. Genet., 1998, 18, 106-108.
11. Polymeropoulos, M.H.; Lavedan, C.; Leroy, E.; Ide, S.E.; Dehejia, A.; Dutra, A.; Pike, B.; Root, H.; Ruhenstein, J.; Boyer, R.; Stenroos, E.S.; Chandrasekharappa, S.; Athanassiadou, A.; Papapetropoulos, T.; Johnson, W.G.; Lazzarini, A.M.; Duvoisin, R.C.; Di Iorio, G.; Golbe, L.I.; Nussbaum, R.L. Mutation in the synuclein gene identified in families with parkinson’s disease, Science, 1997, 276, 2045-2047.
12. Zarranz, J.J; Alegre, J.; Gómez-Esteban, J.C.; Lezcano, E.; Ros, R.; Ampuero, I.; Vidal, L.; Hoenicka, J.; Rodriguez, O.; Atarés, B.; Llorens, V.; Gomez Tortosa, E.; del Ser, T.; Muñoz, D.G.; de Yebenes, J.G. The new mutation, E46K, of synuclein causes Parkinson and Lewy body dementia, Ann. Neurol., 2004, 55, 164-173.
13. Hattori, N.; Kitada, T.; Masamune, H.; Asakawa, S.; Yamamura, Y.; Yoshino, H.; Kobayashi, T.; Yokochi, M.; Wang, M.; Yoritaka, A.; Kondo, T.; Kuzuhara, S.; Nakamura, S.; Shimizu, S.N.; Mizuno, Y. Molecular Genetic Analysis of a Novel Parkin Gene in Japanese Families with Autosomal Recessive Juvenile Parkinsonism: Evidence for Variable Homozygous Deletions in the Parkin Gene in Affected Individuals. Ann. Neurol., 1998, 44, 935-941.
14. Kitada, T.; Asakawa, S.; Hattori, N.; Matsumine, H.; Yamamura, Y.; Minoshima, S.; Yokochi, M.; Mizuno, Y; Shimizu, N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 1998, 392, 605-608.
15. Bonifati, V.; Dekker, M.C.; Vanacore, M.; Fabbrini, G.; Squitieri, F.; Marconi, R.; Antonini, A.; Brustenghi, P.; Dalla, L.A.; De Mari, M.,; Stocchi, F.; Montagna, P.; Gallai, V.; Rizzu, P.; van Swieten, J.C.; Oostra, B.; van Duijn, C.M.; Meco, G. Autosomal recessive early onset parkinsonism is linked to three loci: PARK2, PARK6, and PARK7. Neurol. Sci., 2002, 23, Suppl. 2, S59-S60.
16. Moore, D.J.; Zhang, L.; Troncoco, J.; Lee, M.K.; Hattori, N.; Mizuno, Y.; Dawson, T.M.; Dawson, V.L. Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum. Mol. Genet., 2005, 14, 71-84.
17. Moore, D.J.; West, A.B.; Dawson, V.L.; Dawson, T.M. Molecular pathophysiology of Parkinson's disease. Ann. Rev. Neurosci., 2005, 28, 57-87.
18. Paisan-Ruiz, C.; Jain, S.; Evans, E.W.; Gilkls, W.P.; Simon, J.; van der Brug, M.; Lopez de Munain, A.; Aparicio, S.; Gil, A.M., Khan, N.; Johnson, J.; Martinez, J.R.; Nicholl, D.; Carrera, A.M.; Pena, A.S.; de Silva, R.; Lees, A.; Marti-Masso, J.F.; Perez-Tur, J.; Wood, N.W.; Singleton, A.B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron, 2004, 44, 595-600.
19. Fununyama, M.; Hasegawa, K.; Kowa, H.; Saito, M.; Tsuji, S.; Obata, F. New locus for Parkinson’s disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann. Neurol., 2002, 51, 296-301.
20. Di Fonzo, A.; Rohe, C.F.; Ferreira, J.; Chien, H.F.; Vacca, L.; Stocchi, F.; Guedes, L.; Fabrizio, E.; Manfredi, M.; Vanacore, N; Goldwurm, S.; Breedveld, G; Sampaio, C.; Meco, G.; Barbosa, E., Oostra, B.A., Bonifati, E., The Italian Parkinson Genetics Network. A frequent LRRK2 gene mutation associated autosomal dominant Parkinson’s disease. Lancet, 2005, 365, 412-415.
21. Gilks, W.P.; Abou-Sleiman, P.M.; Ghandi, S.; Jain, S.; Singleton, A.; Lees, A.J.; Shaw, K.; Bhatia, K.P.; Bonifati, V.; Quinn, N.P.; Lynch, J; Healy, D.G.; Holton J.L.; Revesz, T.; Wood, N.W. A common LRRK2 mutation in idiopathic Parkinson’s disease, Lancet, 2005, 365, 415-416.
22. Lesage, S.; Durr, A.; Tazir, M.; Lohman, E.; Leutenegger, A.L.; Janin, S.; Pollak, P.; Brice, A. LRRK2 G2019S as a cause of Parkinson’s disease in North African Arabs. N. Engl. J. Med., 2006, 354, 422-423.
23. Ozelius, L.J.; Senthil, G.; Saunders-Pullman, R.; Ohmann, E.; Deligtisch, A.; Tagliati, M.; Hunt, A.L.; Klein, C.; Henick, B.; Hailpern, S.M.; Lipton, R.B.; Soto-Valencia, J.; Risch, N.; Bressman, S.B. LRRK2 G2019S as a cause of Parkinson’s disease in Ashkenazi Jews, N.Engl. J. Med., 2006, 354, 424-425.
24. Taylor, J.P.; Mata, I.F.; Farrer, M.J. LRRK2: a common pathway for Parkinsonism, pathogenesis and prevention? Trends Mol. Med., 2006, 12, 76-82.
25. Ramsden, N.; Perrin, J.; Ren, Z.; Lee, B.D.; Zinn, N.; Dawson, V.L.; Tam, D.; Bova, M.; Lang, M.; Drewes, G.; Bantscheff, M.; Bard, F.; Dawson, T.M.; Hopf, C. Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson’s disease-related toxicity in human neurons. ACS Chem. Biol., 2011, 6, 1021-1028.
26. West, A.B.; Moore, D.J.; Biskup, S.; Bugayenko, A.; Smith, W.W.; Ross, C.A.; Dawson, V.L.; Dawson, T.M. Parkinson’s diseaseassociated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U.S.A., 2005, 102, 16842-16847.
27. Nolen, B.; Taylor, S.; Ghosh, G. Regulation of protein kinases: Controlling activity through activation segment conformation. Mol. Cell., 2004, 15, 661-675.
28. Dzamko, N.; Deak, M.; Hentati, F.; Reith, A.D.; Prescott, A.R.; Alessi, D.R.; Nichols, R.J. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem. J., 2010, 430, 405-413.
29. Fu, H.; Subramanian, R.R.; Martens, S.C. 14-3-3 proteins: structure, function, and regulation. Ann. Rev. Pharmacol. Toxicol., 2000, 40, 617-647.
30. Cui, J.; Yu, M.; Niu, J.; Yue, Z., Expression of leucine-rich repeat kinase 2 (LRRK2) inhibits the processing of uMtCK to induce cell death in a cell culture model system Biosci. Rep., 2011, 31, 429-437.
31. Niu, J.; Yu, M.; Wang, C.; Xu, Z., Leurcine rich repeat kinase 2 disturbs mitochondrial dynamics via dynamin-like protein, J. Neurochem., 2012, 122, 650-658.
32. Angeles, D.C.; Gan, B.; Onstead, L.; Zhao, Y. Lim, K.; Dachsel, J.; Melrose, H.; Farrer, M.; Wszolek, Z.; Dickson, D.; Tan, E. Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death, Hum. Mutat., 2011, 32, 1390-1397.
33. Kim, B.; Yang, M.-S.; Choi, D.; Kim, J.-S.; Kim, H.-S.; Seol, W.; Choi, S.; Jou, I.; Kim, E.-Y.; Joe, E.-H.; Impaired inflammatory response in murine Lrrk2-knockdown brain microglia, Plos ONE, 2012, 7, 34693.
34. Nakae, J.; Kitamura, T.; Kitamura, Y.; Biggs, W.H.; Arden, K.C.; Accili, D. The forkhead transcription factor Foxo1 regulates adipocyte differentiation. Dev. Cell., 2003, 4 119-129.
35. Pause, A.; Belsham, G.J.; Gingras, A.C.; Donze, O.; Lin, T.A.; Lawrence, J.C.; Sonenberg, N. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function. Nature, 1994, 371, 762-767.
36. Lichtenberg, M.; Mansilla, A.; Zecchini, V.R.; Fleming, A.; Rubinsztein, D.C. The Parkinson’s disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity. Cell Death Dis., 2011, 2, e196.
37. Lee, B.D.; Shin, J.-H; Van Kampen, J.; Petrucelli, L.; West, A.B.; Ko, H.S.; Lee, Y.I.; Maguire-Zeiss, K.A.; Bowers, W.J.; Federoff, H.J.; Dawson, V.L.; Dawson T.M. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson’s disease. Nat. Med., 2010, 16, 998-1000.
38. Anand, V.S.; Reichling, L.J.; Lipinski, K.; Stochaj, W.; Duan, W.; Kelleher, K.; Punhaliya, P.; Brown, E.L.; Reinhart, P.H.; Somberg, R.; Hirst, W.D.; Riddle, S.M.; Braithwaite, S.P. Investigation of leucine-rich repeat kinase 2: Enzymological properties and novel assays. FEBS J., 2009, 276, 466-478.
39. Smith, W.W.; Pei, Z.; Jiang, H. Dawson, V.L.; Dawson, T.M.; Ross, C.A., Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci., 2006, 9, 1231-1233.
40. Greggio, E.; Jain, S.; Kingsbury, A.; Bandopadhyay, R.; Lewis, P.; Kaganovich, A.; van der Brug, M. P.; Beilina, A.; Blackinton, J.; Thomas, K. J.; Ahmad, R.; Miller, D. W.; Kesavapany, S.; Singleton, A.; Lees, A.; Harvey, R.J.; Harvey, K.; Cookson, M. R. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Disease, 2006, 23, 329-341.
41. Smith, W.W.; Pei, Z.; Jiang, H.; Moore, D.J.; Liang, Y.; West, A.B.; Dawson, V.L.; Dawson, T.M.; Ross, C.A. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl. Acad. Sci. U.S.A., 2005,102, 18676-18681.
42. Luzon-Toro, B.; de la Torre, E.R.; Delgado, A.; Perez-Tur, J.; Hilfiker, S. Mechanistic insight into the dominant mode of the Parkinson’s disease associated G2019S LRRK2 mutation, Human Mol. Genet., 2007, 16, 2031-2039.
43. D. MacLeod, J. Dowman, R. Hammond, T. Leete, K. Inoue, A. Abeliovich, The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron, 2006, 52, 587-593.
44. Dusonchet, J.; Kochubey, O.; Stafa, K.; Young, S.M.; Zufferey, R.; Moore, D.J.; Schneider, B.L.; Aebischer, P. A rat model of progressive nigral neurodegeneration induced by the parkinson’s disease-associated G2019S mutation in LRRK2. J. Neurosci., 2011, 31, 907-912.
45. Chen, C.Y.; Weng, Y.H.; Chien, K.Y.; Lin, K.J; Yeh, T.H.; Cheng, Y.P.; Lu, C.S.; Wang, H.L. (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD, Cell Death Differ., 2012, 19, 1-11.
46. Kavanaugh, M.E.; Doddareddy, M.R.; Kassiou, M, The development of CNS-active LRRK2 inhibitors using property-directed optimisation, Bioorganic Med. Chem. Lett., 2013, 23, 3690-3696.
47. Kramer, T.; Lo Monte, F.; Goring, S.; Amombo, G.M.O; Schmidt, B. Small molecule kinase inhibitors for LRRK2 and their application to Parkinson’s disease models. ACS Chem. Neurosci., 2012, 3, 151-160.
48. Jaleel, M.; Nichols, R.J.; Deak, M.; Campbell, D.G.; Gillardon, F.; Knebel, A.; Aleesi, D.R. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson’s disease mutants affect kinase activity, Biochem. J., 2007, 405, 307-317.
49. Gilsbach, B.K.; Ho, F.V.; Vetter, I.R.; Van Hasstert, P.J.M.; Wittinghofer, A.; Kortholt, A. Roco kinase structures give insights into the mechanism of Parkinson disease-related leucinerich-repeat kinase 2 mutations, Proc. Natl. Acad. Sci. U.S.A., 2012, 109, 10322-10327.
50. Dramko, N.; Deak, M.; Hentati, F.; Reith, A.D.; Prescott, A.R.; Alessi, D.R.; Nichols, R.J. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization, Biochem. J., 2010, 430, 405-413.
51. Nichols, R.J.; Dzamko, N.; Hutti, J.E.; Cantley, L.C.; Deak, M.; Moran, J.; Bamborough, P.; Reith, A.D.; Alessi, D.R. Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson’s disease, Biochem. J., 2009, 424, 47-60.
52. Choi, H.G.; Zhang, J.; Deng, X.; Hatcher, J.M.; Patricelli, M.P.; Zhao, Z.; Alessi, D.R.; Gray, N.S.; Brain penetrant LRRK2 inhibitor, ACS Med. Chem. Lett., 2012, 3, 658-662.
53. Chen, H.; Chan, B.K.; Drummond, J.; Estrada, A.A.; Gunzner-Toste, J.; Liu, X.; Liu, Y.; Moffat, J.; Shore, D.; Sweeney, Z.K.; Tran, T.; Wang, S.; Zhao, G.; Zhu, H.; Burdick, D.J. Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling, J. Med.Chem., 2012, 55, 5536-5545.
54. Vancraenenbroeck, R.; De Raeymaecker, J.; Lobbestael, E.; Gao, F.; De Maeyer, M.; Voet, A. Baekelandt, V., Taymans, J.-M. In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2, Front. Mol. Neurosci., 2014, 7, 1-19.
55. Abeliovich, A. LRRK2 regulation of neuronal process morphology, International application, WO2007124096 A2, April 20, 2007.
56. Deng, X.; Dzamko, N.; Prescott, A.; Davies, P.; Liu, Q.; Yang, Q.; Lee, J.-D.; Patricelli, M.P.; Nomanbhoy, T.K.; Alessi, D.R.; Gray, N.S. Characterization of a selective inhibitor of the Parkinson’s disease kinase LRRK2, Nature Chem. Biol., 2011, 7, 203-205.
57. Zhang, J.; Deng, X. H.G. Choi, D.R. Alessi, N.S. Gray, Characterization of TAE684 as a potent LRRK2 kinase inhibitor, Bioorganic Med. Chem. Lett., 2012, 22, 1864-1869.
58. Reith, A.D.; Bamborough, P.; Jandu, K.; Andreotti, D.; Mensah, L.; Dossang, P.; Choi, H.G.; Deng, X.; Zwang, J.; Alessi, D.R.; Gray, N.S. GSK2578215A: A potent and highly selective 2-arylmethyloxy-5-substituent-N-arylbenzamide LRRK2 kinase inhibitor, Bioorganic Med. Chem. Lett, 2012, 22, 5625-5629.
59. Choi, H.G.; Zhang, J.; Deng, X.; Hatcher, J.M.; Patricelli, M.P.; Zhao, Z.; Alessi, D.R.; Gray, N.S. Brain penetrant LRRK2 inhibitor, ACS Med. Chem. Lett., 2012, 3, 658-662.
60. Estrada, A.A.; Liu, X.; Baker-Glenn, C.; Beresford, C. A.; Burdick, D.J.; Chambers, M.; Chan, B.K.; Chen, H.; Ding, X.; Di-Pasquale, A.G.; Dominguez, S. L.; Dotson, J.; Drummond, J.; Flagella, M.; Flynn, S.; Fuji, R.; Gill, A.; Gunzner-Toste, J.; Harris, S.F.; Heffron, T.P.; Kleinheinz, T.; Lee, D.W.; LePichon, C.E.; Lyssikatos, J.P.; Medhurst, A.D.; Moffat, J.G.; Mukund, S.; Nash, K.; Scearce-Levie, K.; Sheng, Z.; Shore, D.G.; Tran, T.; Trivedi, N.; Wang, S.; Zhang, S.; Zhang, X.; Zhao, G.; Zhu, H.; Sweeney, Z.K. Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors, J. Med. Chem., 2012, 55, 9416-9433.
61. Mills, G.B.; Schmandt, R; McGill, M.; Amendola, A.; Hill, M.; Jacobs, K.; May, C.; Rodricks, A.M.; Campbell, S.; Hogg, D. Expression of TTK, a novel human protein kinase, is associated with cell proliferation. J. Biol. Chem., 1992, 267, 16000-16006.
62. Chan, B.K.; Estrada, A.A.; Chen, H.; Atherall, J.; Baker-Glenn, C.; Beresford, A.; Burdick, D.J.; Chambers, M.; Dominguez, S.L.; Drummond, J.; Gill, A.; Kleinheinz, T.; Le Pichon, C.E.; Medhurst, A.D.; Liu, X.; Moffat, J.G.; Nash, K.; Scearce-Levie, K.; Sheng, Z.; Shore, D.G.; Van de Poel, H.; Zhang, S.; Zhu, H.; Sweeney, Z.K. Discovery of a highly selective, brain-penetrant aminopyrazole LRRK2 inhibitor, ACS Med. Chem. Lett., 2013, 4, 85-90.
63. Estrada, A.A.; Chan, B.K.; Baker-Glenn, C.; Beresford, A.; Burdick, D.J.; Chambers, M.; Chen, H.; Dominguez, S.L.; Dotson, J.; Drummond, J.; Flagella, M.; Fuji, R.; Gill, A.; Halladay, J.; Harris, S.F.; Heffron, T.P.; Kleinheinz, T.; Lee, D.W.; Le Pichon, C.E.; Liu, X.; Lyssikatos, J.P.; Medhurst, A.D.; Moffat, J.G.; Nash, K.; Scearce-Levie, K.; Sheng, S.; Shore, D.G.; Wong, S.; Zhang, S.; Zhang, X.; Zhu, H.; Sweeney, Z.K. Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors, J. Med. Chem., 2014, 57, 921-926.
64. Ritchie, T.J.; Macdonald, S.J.F.; Peace, S.; Pickett, S.D.; Luscombe, C.N. The developability of heteroaromatic and heteroaliphatic rings-Do some have a better pedigree as potential drug molecules than others? Med. Chem. Comm., 2012, 3, 1062-1069